FindTrial
Sign In

To compare loteprednol eye drop and tacrolimus eye ointment in chronic allergic conjunctivitis

Comparison of efficacy and safety of short-term low dose 0.03% Tacrolimus eye ointment versus 0.5% Loteprednol etabonate eye drops as first choice in patients with mild to moderate bilateral Vernal keratoconjunctivitis. - TALO

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/04/051590
Enrollment
60
Registered
2023-04-13
Start date
Unknown
Completion date
Unknown
Last updated
2023-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H104- Chronic conjunctivitis

Interventions

Intervention1: Tacrolimus eye ointment 0.03%: Tacrolimus eye ointment 0.03% given two times a day ( morning and night)for 3 weeks followed by tacrolimus eye ointment 0.03 %,one time(at night)for 3 wee

Sponsors

KLE JGMM Medical College and Suchirayu Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Age more than 14 years 2.Active Bilateral Mild to Moderate Vernal Kerato Conjunctivitis

Exclusion criteria

Exclusion criteria: 1.Patients with adenexal abnormalities , glaucoma, contact lens wearer, corneal pathology 2.Patients on immunosuppressive therapy. 3.known hypersensitivity to Tacrolimus eye ointment 4.Pregnancy and Lactation 5.History of topical medication usage in the previous two weeks.

Design outcomes

Primary

MeasureTime frame
Change in the mean score of ocular symptoms and signs at 2nd week, 4th week, 6th week and 8th week from baseline.Timepoint: 2 months—

Secondary

MeasureTime frame
Subjective scoring of symptoms at baseline, 2nd week, 4th week, 6th week and 8th week.Timepoint: 2 months—

Countries

India

Contacts

Public ContactDr Meghana Patil

KLE JGMM Medical College

drmeghana14@gmail.com07204351640

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026